Diligence memo · auto-generated · as of July 2, 2026
Vaxin Inc.
Vaxin Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Vaxin Inc. operates in Biotechnology, based in GAITHERSBURG.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vaxin Inc. has raised $50M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $42M on 2015-03-10.
Most recent recorded round closed around 2015-03-10.
Valuation (modeled)modeled
Provath models Vaxin Inc. at approximately $1.7B (range $130M–$4.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.76× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era. Within the normal band (76% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 11.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 5.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 82% of Biotechnology peers (4293 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Antigenics LLC/DE, Naurex Inc., Fluidigm Corp, Tengion Inc, Spark Therapeutics, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.